Precision Psychiatry Market Size & Growth Forecast 2027–2036, By Segments (End-user, Service Type, Technology, Therapeutic Area), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to Content
Market Size and Growth Outlook
Precision Psychiatry Market size was valued at USD 1.05 billion in 2026 and is anticipated to grow at a 15.51% CAGR from 2027 to 2036, reaching USD 4.44 billion by 2036. The industry revenue for 2027 is assessed at USD 1.19 billion.
Get more details on this report
Request Free Sample ReportPrecision Psychiatry Market Intelligence Snapshot
Regional Market Dynamics
- North America held 43.1% market share in 2026, driven by advanced healthcare infrastructure, personalized medicine adoption, mental health research investment, and growing use of data-driven psychiatric treatment approaches.
- Asia Pacific is expected to grow fastest as mental health awareness, healthcare infrastructure, digital health technologies, telehealth adoption, and investment in research expand access to personalized psychiatric care.
Segment Momentum
- Hospitals and clinics held 57.39% of the market in 2026, reflecting their central role in integrating diagnostic services, genetic assessments, patient monitoring, and individualized treatment planning into psychiatric care.
- Genetic testing accounted for 43.68% of the market in 2026 and is the fastest-growing service type, helping clinicians assess medication response and tolerability to support more individualized psychiatric treatment decisions.
Market Expansion Drivers
- Increasing adoption of personalized and AI-driven psychiatric care.
- Integration with digital mental health platforms and telepsychiatry.
- Expansion into emerging markets with growing mental health awareness.
Leading Market Participants
- Key players in the precision psychiatry market include IBM Watson Health (USA), Mindstrong Health (USA), NeuroFlow (USA), Quartet Health (USA), Pear Therapeutics (USA), Brain Resource (Australia), Spring Health (USA), Psious (Spain), Talkspace (USA).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 1.05 billion
- 2027 Estimated Market Size: USD 1.19 billion
- Projected Market Size: USD 4.44 billion by 2036
- Growth Forecast: 15.51% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: End-user (Hospitals & Clinics) | Service Type (Genetic Testing) | Technology (Next-Generation Sequencing (NGS)) | Therapeutic Area (Depression and Anxiety Disorders)
- Emerging Opportunity Segment: End-user (Hospitals & Clinics) | Service Type (Genetic Testing) | Technology (Next-Generation Sequencing (NGS)) | Therapeutic Area (Depression and Anxiety Disorders)
Market Growth Drivers and Industry Trends
Increasing Adoption of Personalized and AI-Driven Psychiatric Care
The increasing adoption of personalized and artificial intelligence-driven psychiatric care is transforming mental health treatment by supporting more individualized assessment and intervention strategies. Precision psychiatry combines patient-specific clinical information, behavioral characteristics, biological indicators, and digital health data to help clinicians better understand variations in treatment response. AI-enabled analytical tools can assist in identifying patterns across complex patient information and support more informed treatment planning. As healthcare providers increasingly seek approaches that move beyond generalized treatment pathways, the integration of personalized and AI-supported methods is expected to strengthen demand for precision psychiatry solutions.
Integration with Digital Mental Health Platforms and Telepsychiatry
The integration of precision psychiatry with digital mental health platforms and telepsychiatry is expanding access to personalized psychiatric assessment and ongoing care. Digital platforms can facilitate the collection of behavioral, clinical, and patient-reported information outside traditional healthcare settings, creating additional opportunities for continuous monitoring and individualized treatment decisions. Telepsychiatry further enables psychiatric services to reach patients who may face geographic or accessibility barriers. As digital mental health ecosystems become more integrated with clinical workflows, precision psychiatry technologies can increasingly support remote assessment, longitudinal monitoring, and personalized care delivery.
Expansion into Emerging Markets with Growing Mental Health Awareness
The expansion of precision psychiatry into emerging markets is being supported by growing awareness of mental health conditions and increasing recognition of the importance of timely diagnosis and individualized treatment. Improvements in healthcare infrastructure, digital connectivity, and access to specialized psychiatric services are creating opportunities for advanced mental health technologies in these regions. Increasing public and clinical attention toward mental health is also encouraging healthcare systems to explore more effective approaches to diagnosis and treatment management. As awareness continues to improve and digital healthcare adoption expands, precision psychiatry is expected to gain broader relevance across developing healthcare markets.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing adoption of personalized and AI-driven psychiatric care | 5.5% | Short term (≤ 2 yrs) | North America; Europe; Spillover: Asia Pacific | Medium | Fast |
| Integration with digital mental health platforms and telepsychiatry | 5% | Medium term (2–5 yrs) | North America; Europe; Spillover: Asia Pacific | Medium | Moderate |
| Expansion into emerging markets with growing mental health awareness | 5% | Long term (5+ yrs) | Asia Pacific; Latin America; Spillover: North America | Low | Moderate |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
North America held the largest share of the precision psychiatry market in 2026, accounting for 43.1% share in 2026, backed by advanced healthcare infrastructure, increasing adoption of personalized medicine, and growing investments in mental health research and digital healthcare technologies. The region benefits from expanding use of data-driven approaches in psychiatric diagnosis and treatment, along with increasing interest in identifying individualized therapeutic strategies. Growing awareness of mental health conditions, improved access to advanced diagnostic technologies, and increasing integration of genetic, clinical, and behavioral information into treatment decisions are further supporting market development. In addition, continued research into biomarkers and patient-specific treatment approaches is contributing to the adoption of precision psychiatry solutions.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is anticipated to be the fastest-growing region in the precision psychiatry market, driven by increasing awareness of mental health, expanding healthcare infrastructure, and growing adoption of advanced diagnostic and digital health technologies. Rising demand for personalized treatment approaches is encouraging healthcare providers and researchers to explore data-driven methods for improving psychiatric care. Furthermore, increasing investments in healthcare research, improving access to specialized mental health services, and growing adoption of telehealth and digital platforms are creating opportunities for precision psychiatry across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants / StartupsiScaleSparseModerate Dense | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
United States 🇺🇸
Translational Precision PsychiatryThe U.S. precision psychiatry market is centered on translating biomarkers, pharmacogenomics, digital phenotyping, and AI-assisted assessment into clinically actionable decisions. Commercial priorities include evidence generation, integration with behavioral-health workflows, reimbursement pathways, and partnerships that can demonstrate measurable improvements in treatment selection and monitoring.
Germany 🇩🇪
Evidence-Led Clinical AdoptionGermany’s precision psychiatry market will depend heavily on clinical validation, data governance, and integration with established mental-health care pathways. Providers and technology developers should prioritize reproducible biomarker evidence, interoperability, and health-economic justification to support adoption within structured reimbursement and hospital environments.
Japan 🇯🇵
Biomarker Integration FocusJapan’s precision psychiatry market is positioned around integrating biological markers, pharmacogenomic insights, and digital assessment into psychiatric decision-making. Near-term priorities include locally relevant clinical validation, physician usability, and compatibility with established care models, particularly where precision tools can improve medication selection or monitoring.
South Korea 🇰🇷
Digital Psychiatry IntegrationSouth Korea’s precision psychiatry market is closely connected to digital health infrastructure, AI-enabled assessment, and growing interest in individualized treatment strategies. Commercial development should emphasize clinically validated algorithms, seamless integration with psychiatric workflows, and clear evidence that precision tools improve treatment decisions without adding excessive clinical burden.
France 🇫🇷
Public-System Evidence BuildingFrance’s precision psychiatry market requires strong clinical and health-economic evidence to support integration into public healthcare pathways. Priorities include validating biomarkers and digital tools in routine psychiatric settings, establishing clinician trust, and demonstrating practical benefits for treatment selection, monitoring, and patient management.
Italy 🇮🇹
Clinical Pathway LocalizationItaly’s precision psychiatry market presents a need to adapt precision tools to regional healthcare delivery and specialist-led psychiatric pathways. Market participants should focus on locally relevant validation, interoperability, clinician training, and practical reimbursement arguments that can support adoption across varied regional care structures.
Precision Psychiatry Market Share (%), by End-user, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportEnd-user Segment Analysis: Hospitals & Clinics (Largest & Fastest-Growing Segment)
Hospitals & clinics accounted for a 2026 share of 57.39% of the precision psychiatry market, while also emerging as the fastest-growing end-user segment, reflecting their central role in adopting personalized approaches to mental healthcare. These settings provide access to multidisciplinary psychiatric care, diagnostic services, genetic assessments, and patient monitoring capabilities needed to implement precision psychiatry in clinical practice. The growing recognition of differences in treatment response and the need to improve the selection of psychiatric therapies are encouraging healthcare providers to incorporate data-driven approaches into routine care. Hospitals and clinics can integrate clinical history, biological information, and diagnostic insights to support more individualized treatment planning, particularly for patients with complex or treatment-resistant psychiatric conditions. Increasing investment in advanced diagnostic infrastructure, greater awareness of personalized mental healthcare, and the integration of emerging technologies into clinical workflows are further strengthening demand for precision psychiatry services across these healthcare settings.
Service Type Segment Analysis: Genetic Testing (Largest & Fastest-Growing Segment)
Genetic testing accounted for a 2026 share of 43.68% of the precision psychiatry market and is also expected to experience the fastest growth across the service type segment, underscoring its expanding importance in personalized psychiatric care. Genetic testing can provide insights into individual biological characteristics that may influence medication response, treatment tolerability, and susceptibility to certain psychiatric conditions. Its increasing use supports a shift away from generalized treatment approaches toward more individualized therapy selection, particularly where conventional treatment strategies have produced inconsistent outcomes. Growing interest in pharmacogenomic information is also encouraging clinicians to consider genetic factors when evaluating medication options and treatment strategies. As precision psychiatry develops, the integration of genetic testing with clinical assessments and other patient-specific data is expected to strengthen personalized decision-making and expand the role of genetic-based services in psychiatric care.
Technology Segment Analysis: Next-Generation Sequencing (NGS) (Largest & Fastest-Growing Segment)
Next-Generation sequencing (NGS) accounted for a 2026 share of 49.31% of the precision psychiatry market and is also projected to be the fastest-growing technology segment, reflecting its ability to generate detailed genetic information relevant to personalized psychiatric care. Across the technology segment, NGS enables the analysis of multiple genetic targets simultaneously, supporting the identification of genetic variations that may contribute to disease susceptibility, treatment response, and medication-related outcomes. Its capacity to process complex genomic information efficiently makes it increasingly relevant as psychiatric research and clinical practice place greater emphasis on biological factors underlying mental health conditions. The expanding availability of genomic data, improvements in sequencing technologies, and growing integration of genetic insights into clinical decision-making are supporting broader adoption. As precision psychiatry advances toward more individualized diagnosis and treatment strategies, NGS is positioned to play an increasingly important role in translating genomic information into clinically relevant insights.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| End-user | Hospitals & Clinics, Clinical Laboratories, Others | Hospitals & Clinics | Hospitals & Clinics |
| Service Type | Genetic Testing, Biomarker Analysis, Data Analytics & Interpretation Services, Others | Genetic Testing | Genetic Testing |
| Technology | Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunoassay, Mass Spectrometry, Others | Next-Generation Sequencing (NGS) | Next-Generation Sequencing (NGS) |
| Therapeutic Area | Depression and Anxiety Disorders, Schizophrenia and Psychotic Disorders, Bipolar Disorder, Substance Use Disorders, Others | Depression and Anxiety Disorders | Depression and Anxiety Disorders |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Analyst Perspective:
The precision psychiatry market's competitive landscape depends on translating advances in diagnostics, data analytics, and targeted treatments into demonstrable improvements in psychiatric care. Biomarker and pharmacogenomic testing providers must establish that their results meaningfully inform treatment selection, with reproducibility and clinical relevance carrying greater weight than technical accuracy alone. AI-driven diagnostic software adds opportunities to integrate clinical, behavioral, and biological information, although interpretability, data quality, and compatibility with existing clinical workflows influence practical adoption. Targeted neurotherapeutics and novel formulations likewise require evidence of differentiated benefits across specific patient populations. Commercial viability ultimately rests on clinical validation and reimbursement alignment, as providers must demonstrate sufficient value to justify adoption within established care pathways. Promising technologies may face limited uptake when improvements in treatment outcomes remain uncertain.
Prominent players in the precision psychiatry market:
- IBM Watson Health (USA)
- Mindstrong Health (USA)
- NeuroFlow (USA)
- Quartet Health (USA)
- Pear Therapeutics (USA)
- Brain Resource (Australia)
- Spring Health (USA)
- Psious (Spain)
- Talkspace (USA)
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| IBM Watson Health (USA) | |||||||
| Mindstrong Health (USA) | |||||||
| NeuroFlow (USA) | |||||||
| Quartet Health (USA) | |||||||
| Pear Therapeutics (USA) | |||||||
| Brain Resource (Australia) | |||||||
| Spring Health (USA) | |||||||
| Psious (Spain) | |||||||
| Talkspace (USA) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| HMNC Brain Health | June 2026 | Secured a $50 million first tranche of Series B financing led by MEDICE alongside a European licensing partnership to advance its targeted depression therapies KET01 and BH-200, combining growth capital with regional commercialization infrastructure. |
| Alto Neuroscience | May 2026 | Appointed Karuna Therapeutics founder Andrew Miller to its board of directors, strengthening corporate governance and strategic alignment as the company advances its precision psychiatry pipeline toward commercialization. |
| MeOmics | March 2026 | Advanced its personalized mental health technology platform leveraging dedicated innovation funding to expand diagnostic and therapeutic capabilities within the targeted psychiatric treatment landscape. |
| Polaris Genomics | July 2025 | Secured a second $100,000 Maryland Industrial Partnership grant to advance the clinical validation of its proprietary PTSD genomic diagnostic test, accelerating commercialization efforts within precision psychiatric diagnostics. |
| GeneDx | June 2025 | Published SeqFirst study results demonstrating that rapid genomic testing reduced pediatric diagnostic timelines from 289 days to 13 days, accelerating clinical validation and supporting broader market adoption of precision diagnostic platforms. |
| Boehringer Ingelheim | October 2024 | Formed a strategic partnership with Dartmouth’s Center for Technology and Behavioral Health to co-develop digital health platforms for patients and healthcare providers, advancing technology-enabled behavioral healthcare delivery. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Precision Psychiatry Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Patient Stratification Approach | Genetic Stratification, Biomarker-Based Stratification, Clinical Phenotype Stratification, Multimodal Stratification |
| Clinical Workflow Stage | Screening & Diagnosis, Treatment Selection, Treatment Monitoring, Treatment Optimization |
| Reimbursement Model | Fee-for-Service, Value-Based/Rebundled Payment, Public/Government Reimbursement, Self-Pay |
Precision Psychiatry Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Clinical Adoption & Workflow Integration |
|
| Biomarker Validation & Commercialization Pathways |
|
| Reimbursement Models for Personalized Mental Healthcare |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
What is the market valuation of the precision psychiatry market?
What is the anticipated CAGR of the precision psychiatry industry?
How is AI-driven personalization accelerating adoption in precision psychiatry?
How are digital mental health platforms expanding precision psychiatry deployment?
Why do hospitals and clinics dominate the precision psychiatry market?
How is genetic testing shaping growth in the precision psychiatry market?
How does North America maintain its leadership in precision psychiatry?
What is accelerating precision psychiatry adoption across Asia Pacific?
Who holds a significant market share in the precision psychiatry landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook